As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare technology for providers industry, including Privia Health (NASDAQ: PRVA) and its peers.

The healthcare technology sector provides software and data analytics to help hospitals and clinics streamline operations and improve patient outcomes, often through value-based care models. Future growth is expected as providers prioritize digital transformation to manage rising costs and patient demands. Tailwinds include the adoption of AI-driven tools and government incentives for digitization. There are challenges as well, including long sales cycles and slow adoption by providers, who may be resistance to change. Tightening hospital budgets and cybersecurity threats are additional risks that could slow adoption.

The 4 healthcare technology for providers stocks we track reported a strong Q4. As a group, revenues beat analysts’ consensus estimates by 1.8% while next quarter’s revenue guidance was in line.

Luckily, healthcare technology for providers stocks have performed well with share prices up 18.2% on average since the latest earnings results.

Best Q4: Privia Health (NASDAQ: PRVA)

Operating in 13 states and the District of Columbia with over 4,300 providers serving more than 4.8 million patients, Privia Health (NASDAQ: PRVA) is a technology-driven company that helps physicians optimize their practices, improve patient experiences, and transition to value-based care models.

Privia Health reported revenues of $541.2 million, up 17.4% year on year. This print exceeded analysts’ expectations by 4.8%. Overall, it was a stunning quarter for the company with a beat of analysts’ EPS estimates and full-year revenue guidance exceeding analysts’ expectations.

Privia Health scored the biggest analyst estimates beat and highest full-year guidance raise of the whole group. Unsurprisingly, the stock is up 5.4% since reporting and currently trades at $23.87.

Is now the time to buy Privia Health? Access our full analysis of the earnings results here, it’s free.

Evolent Health (NYSE: EVH)

Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE: EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions.

Evolent Health reported revenues of $468.7 million, down 27.5% year on year, in line with analysts’ expectations. The business had a strong quarter with a beat of analysts’ EPS estimates and full-year revenue guidance exceeding analysts’ expectations.

The market seems happy with the results as the stock is up 23.2% since reporting. It currently trades at $3.16.

Is now the time to buy Evolent Health? Access our full analysis of the earnings results here, it’s free.

Weakest Q4: Omnicell (NASDAQ: OMCL)

Driven by the vision of an "Autonomous Pharmacy" with zero medication errors, Omnicell (NASDAQ: OMCL) provides medication management automation and adherence tools that help healthcare systems and pharmacies reduce errors and improve efficiency.

Omnicell reported revenues of $314 million, up 2.3% year on year, in line with analysts’ expectations. It was a mixed quarter as it posted EBITDA guidance for next quarter exceeding analysts’ expectations but a significant miss of analysts’ full-year EPS guidance estimates.

Omnicell delivered the weakest performance against analyst estimates in the group. As expected, the stock is down 21.5% since the results and currently trades at $36.66.

Read our full analysis of Omnicell’s results here.

Astrana Health (NASDAQ: ASTH)

Formerly known as Apollo Medical Holdings until early 2024, Astrana Health (NASDAQ: ASTH) operates a technology-powered healthcare platform that enables physicians to deliver coordinated care while successfully participating in value-based payment models.

Astrana Health reported revenues of $950.5 million, up 42.9% year on year. This print surpassed analysts’ expectations by 2.3%. Overall, it was a strong quarter as it also recorded a beat of analysts’ EPS and revenue estimates.

Astrana Health scored the fastest revenue growth but had the weakest full-year guidance update among its peers. The stock is up 65.8% since reporting and currently trades at $33.71.

Read our full, actionable report on Astrana Health here, it’s free.

Market Update

Late in 2025 into early 2026, there was hand wringing around artificial intelligence. For software companies, the fear was that AI would erode pricing power and compress margins as new tools made it easier to replicate what once required expensive enterprise platforms. Crypto investors had their own version of the same anxiety: if AI agents could trade, allocate capital, and manage wallets autonomously, what exactly was the long-term value of today’s crypto infrastructure?

These concerns triggered a noticeable rotation away from these sectors and into safer havens. But markets rarely dwell on one narrative for long. Spring 2026 came, and the focus shifted abruptly from technological disruption to geopolitical risk. The US’ conflict with Iran became the dominant driver of market psychology, and when geopolitics takes center stage, the script changes quickly. Investors stop debating growth rates and start worrying about oil supply, inflation, and global stability.

Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.